Results 141 to 150 of about 650,104 (308)

Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation

, 2017
Chunguang Yang,1,* Xueyou Ma,1,* Zhihua Wang,1 Xing Zeng,1 Zhiquan Hu,1 Zhangqun Ye,1 Guanxin Shen2 1Department of Urology, Tongji Hospital, 2Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei ...
Hu Z, Ma X, Zeng X, Yang C, Wang Z, Shen G, Ye Z   +6 more
core  

Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer

, 2012
With approximately 240,890 new cases expected in 2011, prostate cancer remains the leading cause of non-melanoma cancer deaths in men. Immunotherapies using viral vector-based delivery systems targeting tumor-specific antigens are being studied.
Mika Stepankiw, Robert J. Amato
core   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

BJU International, EarlyView.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler, Zuzanna Nowicka, Marcin Miszczyk, Giorgio Calleris, Alessandro Dematteis, Malte W. Vetterlein, Simone Albisinni, Henk G Van Der Poel, Paul Cathcart, Giovanni E. Cacciamani, Inderbir S. Gill, Raj A. Persad, Steven Joniau, Rafael Sanchez‐Salas, Joseph A. Smith Jr, Robert Jeffrey Karnes, Mohamed E. Ahmed, Pawel Rajwa, Derya Tilki, Shahrokh F. Shariat, Paolo Gontero, Giancarlo Marra, on behalf of the Young Academic Urologists Prostate Cancer Working Party   +22 more
wiley   +1 more source

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy

EMBO Molecular Medicine
A critical knowledge gap in prostate cancer research is understanding whether castration-tolerant progenitor-like cells that reside in treatment-naïve tumors play a direct role in therapy resistance and tumor progression.
Manon Baurès, Anne-Sophie Vieira Aleixo, Emeline Pacreau, Aysis Koshy, Vanessa Friedrich, Marc Diedisheim, Martin Raigel, Yichao Hua, Charles Dariane, Florence Boutillon, Lukas Kenner, Jean-Christophe Marine, Gilles Laverny, Daniel Metzger, Florian Rambow, Jacques-Emmanuel Guidotti, Vincent Goffin   +16 more
doaj   +1 more source

Metasztikus kasztrációrezisztens prosztatadaganat korszerű kezelése [The modern treatment of metastatic castration-resistant prostate cancer] [PDF]

, 2019
The basic therapy of metastatic prostate carcinoma is androgen deprivation therapy. Unfortunately, almost all patients develop resistance to treatment that leads to castration-resistant prostate cancer.
Maráz Anikó, Géczi Lajos, Bíró Krisztina, Küronya Zsófia   +3 more
core  

Cabazitaxel for the treatment of castration-resistant prostate cancer

, 2011
Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes.
Guru Sonpavde, Oliver Sartor, Neeraj Agarwal   +2 more
core   +1 more source

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

Cancer Science, EarlyView.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota, Taku Naiki, Koji Hatano, Akira Yokomizo, Hiroaki Tsuchiya, Yoko Takahashi, Taku Nakayama, Masaki Yoshida, Hirotsugu Uemura   +8 more
wiley   +1 more source

Castration Resistance [PDF]

, 2020
openaire   +1 more source

O‐GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A‐TRIM22 Interaction

Cancer Science, EarlyView.
Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang, Zhaoheng Jin, Ziyi Li, Weifeng Xu, Yingjie Li, Yueqiang Peng, Jie Dong, Lin Ma, Zhigang Ji   +8 more
wiley   +1 more source

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

The Journal of Clinical Investigation
Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC).
Jing Li, Thomas A. Hilimire, Yueying Liu, Lili Wang, Jiaxin Liang, Balazs Gyorffy, Vitali Sikirzhytski, Hao Ji, Li Zhang, Chen Cheng, Xiaokai Ding, Kendall R. Kerr, Charles E. Dowling, Alexander A. Chumanevich, Zachary T. Mack, Gary P. Schools, Chang-uk Lim, Leigh Ellis, Xiaolin Zi, Donald C. Porter, Eugenia V. Broude, Campbell McInnes, George Wilding, Michael B. Lilly, Igor B. Roninson, Mengqian Chen   +25 more
doaj   +1 more source